Inpart Industry Call for Opportunities

Seeking Novel Therapeutics for Pulmonary Autoimmune and Fibrotic Diseases

A multinational pharmaceutical company is seeking novel treatments for **autoimmune and fibrotic diseases of the lung**. Our client is particularly interested in novel **first-inclass** or **best-in-class therapeutics** for their diseases of interest.

Approaches of Interest:

- Diseases of interest include asthma, COPD and idiopathic pulmonary fibrosis
- Open to a range of modalities, including small molecules, biologics, oral peptides, RNA-based therapeutics, antibodyoligonucleotide conjugates and in vivo cell therapies
- All novel pathways for the above indications will be considered
- Novel targets with in vivo efficacy data for the above diseases are also of interest

Out of Scope:

- Natural products, gene therapy and ex vivo cell therapy approaches
- Drugs with mature targets (with products in Phase 3 or later stages) unless they have a different modality or mechanism of action
- Repurposed or reformulated drugs
- Medical devices

Developmental Stages of Interest:

- Opportunities from preclinical to Phase 2 are within scope
- Opportunities with in vivo validation are of highest interest

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Inclusion of any *in vivo* or clinical data is also encouraged. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations.

Opportunities sought

- Ω Technologies
- 🞓 Academics and expertise
- 🝷 Centres of excellence
- Research projects
- Spinout companies
- Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online <u>here</u>

Deadline: 24th June 2024 - 10:59 pm GMT

Have any questions? Contact our team at <u>discover@in-part.co.uk</u>

